| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VIRUSRES.2011.08.003 |
| P698 | PubMed publication ID | 21864590 |
| P2093 | author name string | Ulrike Blohm | |
| Alma Gedvilaite | |||
| Egle Mazeike | |||
| P2860 | cites work | Cross-reactivity between HLA-A2-restricted FLU-M1:58-66 and HIV p17 GAG:77-85 epitopes in HIV-infected and uninfected individuals | Q24802424 |
| An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow | Q29615498 | ||
| Induction of long-term protective immune responses by influenza H5N1 virus-like particles. | Q30375255 | ||
| Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein | Q34975376 | ||
| Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model | Q34975904 | ||
| Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells | Q36369741 | ||
| Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo | Q36371253 | ||
| Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy | Q36380506 | ||
| Private specificities of CD8 T cell responses control patterns of heterologous immunity | Q36403228 | ||
| Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation | Q36424493 | ||
| Immune surveillance against a solid tumor fails because of immunological ignorance | Q37178041 | ||
| Norwalk virus-like particles as vaccines | Q37706587 | ||
| Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies | Q37743908 | ||
| Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. | Q38884326 | ||
| Multiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus-related hepatocellular carcinoma | Q39885468 | ||
| Murine pneumotropic virus chimeric Her2/neu virus-like particles as prophylactic and therapeutic vaccines against Her2/neu expressing tumors | Q39931841 | ||
| Segments of puumala hantavirus nucleocapsid protein inserted into chimeric polyomavirus-derived virus-like particles induce a strong immune response in mice | Q40525158 | ||
| Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles | Q40745968 | ||
| Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors | Q41010237 | ||
| Fibroblasts as efficient antigen-presenting cells in lymphoid organs | Q41336467 | ||
| Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates | Q41681194 | ||
| Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen | Q43554100 | ||
| Cellular and humoral immunogenicity of hamster polyomavirus-derived virus-like particles harboring a mucin 1 cytotoxic T-cell epitope. | Q45396371 | ||
| Virus-like particles derived from major capsid protein VP1 of different polyomaviruses differ in their ability to induce maturation in human dendritic cells. | Q45413459 | ||
| Generation of monoclonal antibodies of desired specificity using chimeric polyomavirus-derived virus-like particles | Q45419187 | ||
| Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles | Q45508859 | ||
| CD4-independent protective cytotoxic T cells induced in early life by a non-replicative delivery system based on virus-like particles | Q45729231 | ||
| Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines. | Q45733420 | ||
| Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. | Q45733549 | ||
| Formation of immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster polyomavirus major capsid protein. | Q45741599 | ||
| Yeast cells allow high-level expression and formation of polyomavirus-like particles | Q45857869 | ||
| Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo | Q45860175 | ||
| Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitative in vivo comparison | Q47644311 | ||
| Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction | Q59061007 | ||
| Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo. | Q64898418 | ||
| Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo | Q77186082 | ||
| Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes | Q78488941 | ||
| Beneficial therapeutic effects with different particulate structures of murine polyomavirus VP1-coat protein carrying self or non-self CD8 T cell epitopes against murine melanoma | Q81348920 | ||
| Solid tumors "melt" from the inside after successful CD8 T cell attack | Q82133126 | ||
| Innate signaling regulates cross-priming at the level of DC licensing and not antigen presentation | Q84819738 | ||
| P433 | issue | 1 | |
| P921 | main subject | Hamster polyomavirus | Q18974605 |
| P304 | page(s) | 2-10 | |
| P577 | publication date | 2011-08-16 | |
| P1433 | published in | Virus Research | Q15749215 |
| P1476 | title | Induction of insert-specific immune response in mice by hamster polyomavirus VP1 derived virus-like particles carrying LCMV GP33 CTL epitope | |
| P478 | volume | 163 |
| Q38285854 | Antigen delivery by virus-like particles for immunotherapeutic vaccination. |
| Q91644203 | Chimeric Murine Polyomavirus Virus-Like Particles Induce Plasmodium Antigen-Specific CD8+ T Cell and Antibody Responses |
| Q42250611 | Chimeric SV40 virus-like particles induce specific cytotoxicity and protective immunity against influenza A virus without the need of adjuvants. |
| Q42241580 | Immunogenicity of different recombinant rabbit hemorrhagic disease virus-like particles carrying CD8+ T cell epitope from chicken ovalbumin (OVA). |
| Q33812653 | Subviral particle as vaccine and vaccine platform |
| Q39081725 | Synthetic plant virology for nanobiotechnology and nanomedicine |
| Q38603912 | The application of virus-like particles as vaccines and biological vehicles |
| Q62128249 | Virus-like particle-based vaccines for animal viral infections |
| Q38088523 | Virus-like particles: the future of microbial factories and cell-free systems as platforms for vaccine development |
| Q38019283 | Virus-like particles: the new frontier of vaccines for animal viral infections. |
| Q39012245 | Yeast as an expression system for producing virus-like particles: what factors do we need to consider? |
Search more.